41,484 Shares in AtriCure, Inc. $ATRC Acquired by Ieq Capital LLC

Ieq Capital LLC purchased a new position in shares of AtriCure, Inc. (NASDAQ:ATRC) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 41,484 shares of the medical device company’s stock, valued at approximately $1,161,000. Ieq Capital LLC owned about 0.08% of AtriCure as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently bought and sold shares of ATRC. Vanguard Group Inc. boosted its holdings in shares of AtriCure by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 4,903,755 shares of the medical device company’s stock valued at $193,993,000 after purchasing an additional 62,861 shares during the last quarter. BlackRock Inc. acquired a new stake in shares of AtriCure during the 2nd quarter worth $125,198,000. Wellington Management Group LLP raised its position in shares of AtriCure by 8.1% in the 3rd quarter. Wellington Management Group LLP now owns 4,292,087 shares of the medical device company’s stock worth $151,296,000 after buying an additional 322,818 shares during the period. First Light Asset Management LLC raised its position in shares of AtriCure by 32.0% in the 4th quarter. First Light Asset Management LLC now owns 1,175,445 shares of the medical device company’s stock worth $46,501,000 after buying an additional 285,083 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in AtriCure by 8.2% in the first quarter. Dimensional Fund Advisors LP now owns 997,759 shares of the medical device company’s stock valued at $28,466,000 after acquiring an additional 75,862 shares during the last quarter. Hedge funds and other institutional investors own 99.11% of the company’s stock.

Insider Transactions at AtriCure

In other AtriCure news, Director Karen Prange sold 3,564 shares of the stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $38.80, for a total value of $138,283.20. Following the completion of the sale, the director owned 22,809 shares of the company’s stock, valued at $884,989.20. This trade represents a 13.51% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Vinayak Doraiswamy sold 6,000 shares of the stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $38.88, for a total transaction of $233,280.00. Following the completion of the sale, the insider directly owned 86,511 shares of the company’s stock, valued at $3,363,547.68. This trade represents a 6.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 53,616 shares of company stock worth $2,149,994 over the last 90 days. 4.00% of the stock is owned by corporate insiders.

AtriCure Trading Down 1.0%

NASDAQ:ATRC opened at $48.17 on Thursday. The business’s 50-day moving average is $37.09 and its two-hundred day moving average is $32.06. The firm has a market capitalization of $2.45 billion, a PE ratio of 229.39 and a beta of 1.20. AtriCure, Inc. has a 12 month low of $25.36 and a 12 month high of $49.88. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19.

AtriCure (NASDAQ:ATRC) last issued its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. The company had revenue of $153.60 million during the quarter, compared to the consensus estimate of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same quarter in the prior year, the business earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Research analysts predict that AtriCure, Inc. will post 0.2 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on ATRC. Wall Street Zen downgraded AtriCure from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 2nd. Weiss Ratings raised AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 19th. UBS Group decreased their target price on AtriCure from $55.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday, July 28th. Citigroup reissued a “market outperform” rating on shares of AtriCure in a research report on Tuesday, July 21st. Finally, BTIG Research lifted their price target on shares of AtriCure from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, AtriCure presently has an average rating of “Moderate Buy” and a consensus price target of $48.62.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.